TY - JOUR T1 - Comorbidities and sociodemographic factors on COVID-19 fatalities JF - medRxiv DO - 10.1101/2022.05.20.22275397 SP - 2022.05.20.22275397 AU - Jacob Gerken AU - Demi Zapata AU - Daniel Kuivinen AU - Isain Zapata Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/21/2022.05.20.22275397.abstract N2 - Introduction Previous studies have evaluated comorbidities and sociodemographic factors individually or by type but not comprehensively. This study aims to analyze the influence of a wide variety of factors in a single study to better understand the big picture of their effects on case-fatalities.Methods County-level comorbidities, social determinants of health such as income and race, measures of preventive healthcare, age, education level, average household size, population density, and political voting patterns were all evaluated on a national and regional basis. Analysis was performed through Generalized Additive Models and adjusted by CCVI.Results Factors associated with reducing COVID-19 case fatality rates were mostly sociodemographic factors such as age, education and income, and preventive health measures. Obesity, minimal leisurely activity, binge drinking, and higher rates of individuals taking high blood pressure medication were associated with increased case fatality rate in a county. Political leaning influences case case-fatality rates. Regional trends showed contrasting effects where larger household size was protective in the Midwest, yet harmful in Northeast. Notably, higher rates of respiratory comorbidities such as asthma and COPD diagnosis were associated with reduced case-fatality rates in the Northeast. Increased rates of CKD within counties were often the strongest predictor of increased case-fatality rates for several regions.Conclusion Our findings highlight the importance of considering the full context when evaluating contributing factors to case-fatality rates. The spectrum of factors identified in this study must be analyzed in the context of one another and not in isolation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo special funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:---White House COVID-19 Team. COVID-19 Community Profile Report. Accessed March 31, 2022. https://healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-d9w9 ---US Center for Disease Control. 2020 PLACES. Local data for better health county data 2020 release. Published 2021. Accessed March 12, 2021. https://chronicdata.cdc.gov/500-Cities-Places/PLACES-Local-Data-for-Better-Health-County-Data-20/swc5-untb/data ---US Census Bureau. Average Household Size and Population Density - County. Published 2020. https://covid19.census.gov/datasets/USCensus::average-household-size-and-population-density-county/explore?location=3.973504%2C0.315550%2C2.69&showTable=true ---US Census Bureau. Gazetteer Files. Published 2021. https://www.census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html ---Lab MITED and S. County Presidential Election Returns 2000-2020. doi:doi:10.7910/DVN/VOQCHQ ---US Census Bureau. 2020 Decennial United States Census. Published 2021. https://www.census.gov/data.html ---US Census Bureau. 2019 American community survey 5-year public use microdata samples. Published 2020. Accessed March 12, 2021. https://data.census.gov/cedsci/ I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study is publicly available. Curated datasets can be made available with a reasonable request to the corresponding author. https://healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-d9w9 https://chronicdata.cdc.gov/500-Cities-Places/PLACES-Local-Data-for-Better-Health-County-Data-20/swc5-untb/data https://covid19.census.gov/datasets/USCensus::average-household-size-and-population-density-county/explore?location=3.973504%2C0.315550%2C2.69&showTable=true https://www.census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html doi:doi:10.7910/DVN/VOQCHQ https://www.census.gov/data.html https://data.census.gov/cedsci/ ER -